Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks

被引:36
作者
Suzuki, Norihiko [1 ]
Nakagawa, Fumio [1 ]
Nukatsuka, Mamoru [1 ]
Fukushima, Masakazu [1 ]
机构
[1] Taiho Pharmaceut Co Ltd, Tokushima Res Ctr, Tokushima 7710194, Japan
关键词
trifluorothymidine; 5-fluorouracil; 5-fluoro-2 '-deoxyuridine; DNA double-strand break; CELL-CYCLE ARREST; FLUORINATED PYRIMIDINES; THYMIDYLATE SYNTHETASE; CANCER-CELLS; COMBINATION ANTIMETABOLITE; CARCINOMA-CELLS; 5-FLUOROURACIL; INHIBITION; MECHANISM; REPAIR;
D O I
10.3892/etm.2011.244
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
TAS-102 is an oral anticancer drug composed of trifluorothymidine (TFT) and TPI (an inhibitor of thymidine phosphorylase that strongly inhibits the biodegradation of TFT). Similar to 5-fluorouracil (5FU) and 5-fluoro-2'-deoxyuridine (FdUrd), TFT also inhibits thymidylate synthase (TS), a rate-limiting enzyme of DNA biosynthesis, and is incorporated into DNA. TFT exhibits an anticancer effect on colorectal cancer cells that have acquired 5FU and/or FdUrd resistance as a result of the overexpression of TS. Therefore, we examined the mode of action of TFT-induced DNA damage after its incorporation into DNA. When HeLa cells were treated with TFT, the number of ring open aldehyde forms at apurinic/apyrimidinic sites increased in a dose-dependent manner, although we previously reported that no detectable excisions of TFT paired to adenine were observed using uracil DNA glycosylases, thymine DNA glycosylase or methyl-CpG binding domain 4 and HeLa whole cell extracts. To investigate the functional mechanism of TFT-induced DNA damage, we measured the phosphorylation of ATR, ATM, BRCA2, chk1 and chk2 in nuclear extracts of HeLa cells after 0, 24, 48 or 72 h of exposure to an IC50 concentration of TFT, FdUrd or 5FU using Western blot analysis or an enzyme-linked immunosorbent assay (ELISA). Unlike FdUrd and 5FU, TFT resulted in an earlier phosphorylation of ATR and chk1 proteins after only 24 h of exposure, while phosphorylated ATM, BRCA2 and chk2 proteins were detected after more than 48 h of exposure to TFT. These results suggest that TFT causes single-strand breaks followed by double strand breaks in the DNA of TFT-treated cells. TFT (as TAS-102) showed a more potent antitumor activity than oral 5FU on CO-3 colon cancer xenografts in mice, and such antitumor potency was supported by the increased number of double-strand breaks occurring after single-strand breaks in the DNA of the TFT-treated tumors. These results suggest that TFT causes single-strand breaks after its incorporation into DNA followed by double-strand breaks, resulting in DNA damage. This effect of TFT on DNA may explain its potent anticancer activity in cancer therapy.
引用
收藏
页码:393 / 397
页数:5
相关论文
共 24 条
  • [1] Backus HHJ, 2000, ONCOL RES, V12, P231
  • [2] ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2
    Beucher, Andrea
    Birraux, Julie
    Tchouandong, Leopoldine
    Barton, Olivia
    Shibata, Atsushi
    Conrad, Sandro
    Goodarzi, Aaron A.
    Krempler, Andrea
    Jeggo, Penny A.
    Loebrich, Markus
    [J]. EMBO JOURNAL, 2009, 28 (21) : 3413 - 3427
  • [3] Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent
    Bijnsdorp, I. V.
    Kruyt, F. A.
    Gokoel, S.
    Fukushima, M.
    Peters, G. J.
    [J]. CANCER SCIENCE, 2008, 99 (11) : 2302 - 2308
  • [4] Regulation of DNA repair throughout the cell cycle
    Branzei, Dana
    Foiani, Marco
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2008, 9 (04) : 297 - 308
  • [5] EFFECTS OF 5-TRIFLUOROMETHYLDEOXYURIDINE UPON DEOXYTHYMIDINE KINASE
    BRESNICK, E
    WILLIAMS, SS
    [J]. BIOCHEMICAL PHARMACOLOGY, 1967, 16 (03) : 503 - &
  • [6] Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance
    Brown, EJ
    Baltimore, D
    [J]. GENES & DEVELOPMENT, 2003, 17 (05) : 615 - 628
  • [7] DEXTER DL, 1972, CANCER RES, V32, P247
  • [8] MECHANISM-BASED INHIBITION OF THYMIDYLATE SYNTHASE BY 5-(TRIFLUOROMETHYL)-2'-DEOXYURIDINE 5'-MONOPHOSPHATE
    ECKSTEIN, JW
    FOSTER, PG
    FINERMOORE, J
    WATAYA, Y
    SANTI, DV
    [J]. BIOCHEMISTRY, 1994, 33 (50) : 15086 - 15094
  • [9] Emura T, 2004, INT J ONCOL, V25, P571
  • [10] Emura T, 2004, INT J MOL MED, V13, P249